Moderna, Inc. $MRNA Stock Bought by Candriam S.C.A.

Candriam S.C.A. grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 24.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 384,828 shares of the company’s stock after acquiring an additional 75,632 shares during the quarter. Candriam S.C.A. owned about 0.10% of Moderna worth $74,377,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Western Pacific Wealth Management LP purchased a new position in Moderna in the 3rd quarter valued at about $29,000. Next Level Wealth Planning LLC purchased a new stake in shares of Moderna during the third quarter worth about $34,000. Ramsey Quantitative Systems purchased a new stake in shares of Moderna during the third quarter worth about $40,000. Fortitude Family Office LLC grew its holdings in shares of Moderna by 53.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after buying an additional 77 shares in the last quarter. Finally, MADDEN SECURITIES Corp acquired a new position in shares of Moderna in the third quarter valued at approximately $55,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

MRNA stock opened at $254.19 on Friday. The stock has a 50-day moving average price of $191.85 and a two-hundred day moving average price of $91.51. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $267.50. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The company has a market cap of $101.48 billion, a PE ratio of -35.80 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm’s revenue was up 29.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.51) earnings per share. As a group, research analysts predict that Moderna, Inc. will post -6.11 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on MRNA shares. JPMorgan Chase & Co. raised their target price on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. CLSA upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Berenberg Bank increased their price target on Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. UBS Group reissued a “neutral” rating on shares of Moderna in a research note on Tuesday, September 22nd. Finally, Brookline Capital Markets restated a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $107.10.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year, and earnings of $0.38 per share, far ahead of analysts’ expectations for a loss. Stronger overseas COVID-19 vaccine sales helped drive the results. Reuters report on revenue and demand
• Positive Sentiment: Management raised its 2026 revenue-growth forecast to 15%–25%, from a prior outlook of up to 10%. The company also said it plans to reduce research and development spending, supporting its near-term financial performance. CNBC outlook report
• Positive Sentiment: Health Canada authorized Moderna’s seasonal flu and flu-COVID combination vaccines for adults 50 and older, opening a potential new market for its mRNA products. CBC report on Canadian approvals
• Positive Sentiment: Investors are also watching prospects for Moderna’s cancer vaccine: CEO Stéphane Bancel said it could have potential beyond melanoma. That adds pipeline excitement, though future commercial value remains uncertain. Yahoo Finance report on cancer vaccine prospects
• Neutral Sentiment: Moderna and GSK settled a patent dispute involving Moderna’s COVID and RSV shots. The settlement removes a source of legal uncertainty, but the available report does not specify its financial terms. Reuters report on patent settlement
• Negative Sentiment: The sharp rally has heightened concerns that expectations for the cancer-vaccine pipeline may be running ahead of near-term revenue potential. Moderna’s longer-term prospects still depend on sustaining vaccine sales and turning pipeline advances into commercial products. Barron’s analysis of Moderna’s earnings and valuation

Insider Transactions at Moderna

In related news, CFO Jamey Mock sold 34,836 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the sale, the president directly owned 1,636,565 shares of the company’s stock, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by company insiders.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.